论文部分内容阅读
目的 比较三组不同联合方案对晚期非小细胞肺癌的疗效和毒性。方法 统计分析平消胶囊 (加丝裂霉素、长春酰胺、顺铂 )方案、MVP方案及CAP(环磷酰胺、阿霉素、顺铂 )方案治疗的 10 2例晚期非小细胞肺癌的临床资料。结果 平消胶囊加MVP组有效率为 5 2 9% (18/34) ,其中完全缓解 2例 ;MVP组有效率为 39 4% (13/33) ;CAP组有效率为 2 8 6 % (10 /35 )。平消胶囊加MVP组与CAP组差异有显著性。平消胶囊加MVP组癌胚抗原测定 (CEA)下降至正常以下为 75 % ;MVP组CEA下降至正常以下为 75 1% ;CAP组CEA下降至正常以下 43 8%。平消胶囊加MVP组与CAP组CEA下降至正常值以下差异有显著性 (P <0 0 5 )。毒副反应 :平消胶囊加MVP组较对照组明显少而轻。结论 平消胶囊联合化疗治疗肺癌安全有效 ,值得推广应用
Objective To compare the efficacy and toxicity of three different combination regimens in advanced non-small cell lung cancer. Methods The clinical data of 102 cases of advanced non-small cell lung cancer treated with Pingxiao capsule (mitomycin C, vincristine, cisplatin), MVP and CAP (cyclophosphamide, doxorubicin, cisplatin) data. Results The effective rate of Pingxiao capsule plus MVP group was 52.9% (18/34), of which 2 cases were completely relieved. The effective rate was 39 4% (13/33) in MVP group, and the effective rate in CAP group was 286% 10/35). Pingxiao capsule plus MVP group and CAP group differences were significant. CEA of Pingxiao capsule plus MVP group decreased to 75% below normal; CEA of MVP group decreased to 75 1% below normal; CEA of CAP group decreased to 438% below normal. The level of CEA in Pingxiao capsule plus MVP group was lower than normal group (P <0.05). Toxicity: Pingxiao capsule plus MVP group was significantly less than the control group and light. Conclusion Pingxiao capsule combined with chemotherapy for lung cancer is safe and effective, which is worth popularizing and applying